Current Report Filing (8-k)
November 07 2018 - 9:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2018
Aquinox Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36327
|
|
98-0542593
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
450 - 887 Great Northern Way,
Vancouver, B.C.
Canada,
V5T 4T5
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code:
(604) 629-9223
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition
On November 7, 2018, Aquinox Pharmaceuticals, Inc. (the Company) issued a press release announcing financial results for the
quarter ended September 30, 2018. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference.
The information in this current report on Form
8-K
and the press release attached as Exhibit 99.1
hereto is being furnished, but shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and is not incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
Aquinox Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Kamran Alam
|
Name:
|
|
Kamran Alam
|
Title:
|
|
Chief Financial Officer
|
Date: November 7, 2018
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
From Sep 2023 to Sep 2024